{"basic_info": {"ticker": "2550", "exchange": "XSHE", "bloomberg_ticker": "002550 CH Equity", "name": "CHANGZHOU QIANHONG BIOPHAR-A", "industry": "Pharmaceuticals", "name_chinese_simplified": "千红制药", "period": "2020", "market_value": 5401072640, "total_income": 654688083, "ccy": "人民币元", "shariah_compliance_summary": "compliant"}, "business_activity_screening": {"summary": [{"shariah_compliance": "compliant", "income": 654455807, "business_income_over_total_income": 0.9996452111989947}, {"shariah_compliance": "unknown", "income": 232275, "business_income_over_total_income": 0.0003547872735603162}], "details": [{"business_activity_cn": "原料药系列", "business_activity_en": "API Series", "income": 322136987, "business_income_over_total_income": 0.4920465109489399, "shariah_compliance": "compliant"}, {"business_activity_cn": "制剂药品系列", "business_activity_en": "Pharmaceutical preparations series", "income": 332318820, "business_income_over_total_income": 0.5075987002500548, "shariah_compliance": "compliant"}, {"business_activity_cn": "其他业务", "business_activity_en": "Other business", "income": 232275, "business_income_over_total_income": 0.0003547872735603162, "shariah_compliance": "unknown"}]}, "financial_screening": [{"item": "Debt to Market Capitalization", "amount": 0.008668747205958324, "shariah_compliance": "compliant", "amount_over_market_value": 0.008668747205958324}]}